Company logo

PLSE - Pulse Biosciences, Inc.

NASDAQ -> Healthcare -> Medical Instruments & Supplies
Hayward, United States
Type: Equity

PLSE price evolution
PLSE
(in millions $) 30 Jun 2022 31 Mar 2022 31 Dec 2021 30 Sep 2021
Current assets
Cash $14.8 $12.68 $28.61 $41.99
Short term investments
Net receivables $0.01 $0.02 $0.06 $0.07
Inventory $7.87 $7.49 $5.82 $4.28
Total current assets $23.74 $22.16 $36.63 $49.21
Long term investments
Property, plant & equipment $10.82 $11.16 $11.25 $11.4
Goodwill & intangible assets $5.67 $5.84 $6.01 $6.17
Total noncurrent assets $16.86 $17.37 $17.62 $17.94
Total investments
Total assets $40.6 $39.53 $54.25 $67.15
Current liabilities
Accounts payable $1.95 $3.49 $2.9 $2.71
Deferred revenue $0.03 $0.02 $0.02 $0.01
Short long term debt $0.83 $0.8 $1.21 $1.83
Total current liabilities $7.56 $8.9 $8.52 $9.52
Long term debt $9.62 $9.83 $10.04 $10.24
Total noncurrent liabilities $9.62 $9.83 $10.04 $10.24
Total debt $10.45 $10.63 $11.25 $12.08
Total liabilities $17.18 $18.74 $18.56 $19.76
Shareholders' equity
Retained earnings -$267.47 -$253.47 -$236.2 -$220.78
Other shareholder equity
Total shareholder equity $23.41 $20.8 $35.69 $47.39
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Current assets
Cash $28.61 $12.46 $6.9 $51.1
Short term investments $8.01 $18.5 $8.48
Net receivables $0.06
Inventory $5.82
Total current assets $36.63 $22.34 $26.4 $60.36
Long term investments
Property, plant & equipment $11.25 $11.92 $7.68 $2.17
Goodwill & intangible assets $6.01 $6.67 $7.34 $8
Total noncurrent assets $17.62 $18.95 $15.51 $10.28
Total investments $8.01 $18.5 $8.48
Total assets $54.25 $41.29 $41.91 $70.64
Current liabilities
Accounts payable $2.9 $1.72 $1.96 $1.27
Deferred revenue $0.02
Short long term debt $1.21 $0.54
Total current liabilities $8.52 $7.58 $4.46 $3.11
Long term debt $10.04 $10.81 $6.72
Total noncurrent liabilities $10.04 $10.81 $6.72 $1.2
Total debt $11.25 $11.36 $6.72
Total liabilities $18.56 $18.4 $11.18 $4.31
Shareholders' equity
Retained earnings -$236.2 -$172.54 -$122.69 -$75.72
Other shareholder equity -$0 $0 -$0
Total shareholder equity $35.69 $22.89 $30.74 $66.33
(in millions $) 30 Jun 2022 31 Mar 2022 31 Dec 2021 30 Sep 2021
Revenue
Total revenue $0.27 $0.44 $0.84 $0.57
Cost of revenue $1.34 $0.91 $1.24 $0.73
Gross Profit -$1.08 -$0.47 -$0.4 -$0.15
Operating activities
Research & development $5.46 $6.77 $5.66 $6.46
Selling, general & administrative $7.48 $10.04 $9.36 $7.66
Total operating expenses $12.94 $16.81 $15.01 $14.12
Operating income -$14.01 -$17.27 -$15.41 -$14.27
Income from continuing operations
EBIT -$14.01 -$17.27 -$16.7 -$14.27
Income tax expense
Interest expense -$0.02 -$1.29 $0.01
Net income
Net income -$14 -$17.27 -$15.42 -$14.28
Income (for common shares) -$14 -$17.27 -$15.42 -$14.28
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Revenue
Total revenue $1.42
Cost of revenue $1.97
Gross Profit -$0.55
Operating activities
Research & development $28.64 $26.44 $24.96 $17.25
Selling, general & administrative $33.82 $22.86 $22.33 $20.05
Total operating expenses $62.46 $49.97 $47.95 $37.96
Operating income -$63.01 -$49.97 -$47.95 -$37.96
Income from continuing operations
EBIT -$64.31 -$49.85 -$46.97 -$37.55
Income tax expense
Interest expense -$0.65
Net income
Net income -$63.66 -$49.85 -$46.97 -$37.55
Income (for common shares) -$63.66 -$49.85 -$46.97 -$37.55
(in millions $) 30 Jun 2022 31 Mar 2022 31 Dec 2021 30 Sep 2021
Net income -$14 -$17.27 -$15.42 -$14.28
Operating activities
Depreciation $0.35 $0.33 $0.3 $0.29
Business acquisitions & disposals
Stock-based compensation $1.71 $2.01 $3.61 $1.58
Total cash flows from operations -$12.82 -$15.59 -$12.69 -$13.35
Investing activities
Capital expenditures -$0.02 -$0.28 -$0.13 -$0.16
Investments
Total cash flows from investing -$0.02 -$0.28 -$0.13 -$0.16
Financing activities
Dividends paid
Sale and purchase of stock $14.96 $0.37 $0.11 $8.74
Net borrowings -$0.44 -$0.66 $0.21
Total cash flows from financing $14.96 -$0.07 -$0.55 $8.07
Effect of exchange rate
Change in cash and equivalents $2.12 -$15.94 -$13.38 -$5.43
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Net income -$63.66 -$49.85 -$46.97 -$37.55
Operating activities
Depreciation $1.15 $1.09 $1.16 $1.31
Business acquisitions & disposals
Stock-based compensation $14.6 $10.07 $11.29 $12.34
Total cash flows from operations -$54.1 -$35.37 -$34.19 -$23.9
Investing activities
Capital expenditures -$0.44 -$0.44 -$0.61 -$0.28
Investments $8 $10.48 -$9.49 $26.39
Total cash flows from investing $7.56 $10.04 -$10.1 $26.12
Financing activities
Dividends paid
Sale and purchase of stock $62.51 $30.89 $0.69 $45.61
Net borrowings $0.41
Total cash flows from financing $62.69 $30.89 $0.08 $45.5
Effect of exchange rate
Change in cash and equivalents $16.15 $5.56 -$44.2 $47.72
Fundamentals
Market cap $98.38M
Enterprise value $94.03M
Shares outstanding 37.13M
Revenue $2.13M
EBITDA -$61.00M
EBIT -$62.26M
Net Income -$60.97M
Revenue Q/Q InfinityT%
Revenue Y/Y N/A
P/E ratio -1.61
EV/Sales 44.21
EV/EBITDA -1.54
EV/EBIT -1.51
P/S ratio 46.25
P/B ratio 4.20
Book/Share 0.63
Cash/Share 0.40
EPS -$1.64
ROA -121.01%
ROE -191.59%
Debt/Equity 0.52
Net debt/EBITDA -0.04
Current ratio 3.14
Quick ratio 2.10